AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24419000 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-stroke shoulder pain group
Number of subjects: 49
Study 24419000 — intervention group
Group type: COMPARATOR
Intervention: Stroke groups (with and without shoulder pain)
Number of subjects: 49
Study 21917058 — intervention group
Group type: EXPERIMENTAL
Intervention: air-Q intubating laryngeal airway (ILA)
Number of subjects: 50
Study 21917058 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal Mask Airway‐Unique (LMA‐U)
Number of subjects: 50
Study 20144497 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 14
Study 20144497 — intervention group
Group type: COMPARATOR
Intervention: Non-PRF treatment (control)
Number of subjects: 14
Study 17878468 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (including exercise training, education, psychosocial support, and nutritional intervention)
Number of subjects: 0
Study 17878468 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of optimal bronchodilator therapy and/or supplemental oxygen therapy with exercise training
Number of subjects: 0
Study 16344836 — intervention group
Group type: EXPERIMENTAL
Intervention: MAS XR 30 mg
Number of subjects: 32
Study 16344836 — intervention group
Group type: COMPARATOR
Intervention: MAS XR 20 mg
Number of subjects: 32
Study 16344836 — intervention group
Group type: COMPARATOR
Intervention: MAS XR 40 mg
Number of subjects: 32
Study 16344836 — intervention group
Group type: COMPARATOR
Intervention: MAS XR 60 mg
Number of subjects: 32
Study 12117301 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperhydration induced by ingestion of glycerol (1.1 g/kg body mass) and fluid (21.4 mL/kg body mass)
Number of subjects: 8
Study 12117301 — intervention group
Group type: COMPARATOR
Intervention: Euhydration (control trial)
Number of subjects: 8
Study 11697710 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine diphosphate (ADP) induced platelet aggregation
Number of subjects: 0
Study 11697710 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen induced platelet aggregation
Number of subjects: 0
Study 11697710 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean platelet count before therapy
Number of subjects: 0
Study 11697710 — intervention group
Group type: EXPERIMENTAL
Intervention: Ristocetin induced platelet aggregation
Number of subjects: 0
Study 11697710 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine induced platelet aggregation
Number of subjects: 0
Study 11697710 — intervention group
Group type: EXPERIMENTAL
Intervention: ADP and collagen induced platelet aggregations
Number of subjects: 0
Study 9597244 — intervention group
Group type: COMPARATOR
Intervention: Four-drug regimen (standard treatment)
Number of subjects: 0
Study 9597244 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-drug regimen (four drugs plus levofloxacin)
Number of subjects: 0
Study 9597244 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 months of intermittent therapy with isoniazid and rifampin
Number of subjects: 0
Study 9597244 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months of intermittent therapy with isoniazid and rifampin
Number of subjects: 0
Study 7939999 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal fusion for idiopathic scoliosis
Number of subjects: 53
Study 7939999 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal fusion for degenerative scoliosis
Number of subjects: 53
Study 7939999 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal fusion (overall)
Number of subjects: 53
Study 3108009 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (Nitroderm‐TTS)
Number of subjects: 9
Study 3108009 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmucosal nitroglycerin (Trinitrolong)
Number of subjects: 9
Study 3108009 — intervention group
Group type: COMPARATOR
Intervention: Sublingual nitroglycerin
Number of subjects: 9
Study 31278521 — intervention group
Group type: EXPERIMENTAL
Intervention: LAD lesions
Number of subjects: 1235
Study 31278521 — intervention group
Group type: EXPERIMENTAL
Intervention: LCx lesions
Number of subjects: 1235
Study 31278521 — intervention group
Group type: EXPERIMENTAL
Intervention: RCA lesions
Number of subjects: 1235
Study 31278521 — intervention group
Group type: EXPERIMENTAL
Intervention: εs (LAD, RCA) and GLS (LCx)
Number of subjects: 1235
Study 29440149 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal cachexia intervention (MENAC trial) including non-steroidal anti-inflammatory drugs, eicosapentaenoic acid, physical exercise program (resistance and aerobic training), dietary counselling, and oral nutritional supplements.
Number of subjects: 0
Study 29440149 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 0
Study 28164458 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser
Number of subjects: 38
Study 28164458 — intervention group
Group type: COMPARATOR
Intervention: Intense pulsed light (IPL)
Number of subjects: 38
Study 26170027 — intervention group
Group type: EXPERIMENTAL
Intervention: RTA 408 Lotion (0.5%, 1%, and 3%) applied twice daily for 14 days
Number of subjects: 0
Study 26170027 — intervention group
Group type: EXPERIMENTAL
Intervention: RTA 408 Lotion (3%) applied twice daily to a 100-cm² site for 14 days
Number of subjects: 0
Study 26170027 — intervention group
Group type: EXPERIMENTAL
Intervention: RTA 408 Lotion (3%) applied twice daily to a 500-cm² site for 28 days
Number of subjects: 0
Study 26170027 — intervention group
Group type: COMPARATOR
Intervention: Lotion vehicle applied as control
Number of subjects: 0
Study 23682979 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate antibiotic treatment
Number of subjects: 0
Study 23682979 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic treatment
Number of subjects: 0
Study 23682979 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed antibiotic prescribing (DAP) with structured advice to use a course of antibiotics if symptoms worsen or do not improve (prescription given to patient)
Number of subjects: 0
Study 23682979 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed antibiotic prescribing (DAP) with structured advice to use a course of antibiotics if symptoms worsen or do not improve (prescription left at the reception of the primary care centre 3 days after the first medical visit)
Number of subjects: 0
Study 21845445 — intervention group
Group type: EXPERIMENTAL
Intervention: FRG-E (500 μg mouse(‐1))
Number of subjects: 0
Study 21845445 — intervention group
Group type: COMPARATOR
Intervention: NFRG-E
Number of subjects: 0
Study 21845445 — intervention group
Group type: EXPERIMENTAL
Intervention: FRG-E
Number of subjects: 0
Study 19138952 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 0
Study 19138952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16652320 — intervention group
Group type: EXPERIMENTAL
Intervention: DAART
Number of subjects: 250
Study 16652320 — intervention group
Group type: EXPERIMENTAL
Intervention: IACM
Number of subjects: 250
Study 16652320 — intervention group
Group type: COMPARATOR
Intervention: SOC
Number of subjects: 250
Study 12733686 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowering intraocular pressure (IOP) through various treatments, specific interventions not detailed, duration not specified.
Number of subjects: 0
Study 12733686 — intervention group
Group type: EXPERIMENTAL
Intervention: Setting and achieving a target IOP range, specific interventions not detailed, duration not specified.
Number of subjects: 0
Study 12733686 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 11009854 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) technique
Number of subjects: 1418
Study 11009854 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no TM)
Number of subjects: 1418
Study 8670711 — intervention group
Group type: EXPERIMENTAL
Intervention: Labeled Magnitude Scale (LMS)
Number of subjects: 0
Study 8670711 — intervention group
Group type: COMPARATOR
Intervention: Magnitude Estimation (ME)
Number of subjects: 0
Study 1733754 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate therapy (VPA)
Number of subjects: 30
Study 1733754 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 31408474 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I: delayed (> 3 months)
Number of subjects: 1232
Study 31408474 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II: prompt (24-48 hours)
Number of subjects: 1232
Study 31408474 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III: immediate (< 24 hours)
Number of subjects: 1232
Study 31408474 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall HPV prevalence
Number of subjects: 1232
Study 29996802 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyophilised vaccines (BCG, Measles, Yellow Fever)
Number of subjects: 80
Study 29996802 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-dose/single dose vials of liquid vaccines
Number of subjects: 80
Study 29996802 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge assessment of health workers
Number of subjects: 80
Study 29996802 — intervention group
Group type: EXPERIMENTAL
Intervention: National projected wastage targets
Number of subjects: 80
Study 27514506 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil (80 mg) and chlorthalidone (25 mg) in fasted condition
Number of subjects: 48
Study 27514506 — intervention group
Group type: COMPARATOR
Intervention: Azilsartan medoxomil (80 mg) and chlorthalidone (25 mg) 30 minutes after a high‐fat meal
Number of subjects: 48
Study 27514506 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination (FDC) of azilsartan medoxomil and chlorthalidone in fasted condition
Number of subjects: 48
Study 27514506 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose combination (FDC) of azilsartan medoxomil and chlorthalidone 30 minutes after a high‐fat meal
Number of subjects: 48
Study 24747488 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based Behavioral Activation for Depression (BATD) treatment delivered via web-based video technology
Number of subjects: 0
Study 24747488 — intervention group
Group type: COMPARATOR
Intervention: In-office Behavioral Activation for Depression (BATD) treatment
Number of subjects: 0
Study 23285070 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg L-dopa (Madopar)
Number of subjects: 0
Study 23285070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20469975 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan 5/80 mg
Number of subjects: 698
Study 20469975 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 698
Study 20469975 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan 5/80 mg (subgroup n = 82)
Number of subjects: 698
Study 20469975 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (subgroup n = 82)
Number of subjects: 698
Study 20469975 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan
Number of subjects: 698
Study 20469975 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 698
Study 17520207 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary unflanged pancreatic duct stent (5-Fr pigtail PS)
Number of subjects: 64
Study 17520207 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stenting)
Number of subjects: 64
Study 15667798 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine combined with esmolol (1:10)
Number of subjects: 20
Study 15667798 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerine combined with esmolol (1:10)
Number of subjects: 20
Study 12410745 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 40
Study 12410745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10221486 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoglobulin (1.5 mg/kg intravenously)
Number of subjects: 72
Study 10221486 — intervention group
Group type: COMPARATOR
Intervention: Atgam (15 mg/kg intravenously)
Number of subjects: 72
Study 8590509 — intervention group
Group type: EXPERIMENTAL
Intervention: 13.5 mg hyperbaric bupivacaine 0.75% + 25 micrograms fentanyl intrathecal (Group II)
Number of subjects: 43
Study 8590509 — intervention group
Group type: COMPARATOR
Intervention: 13.5 mg hyperbaric bupivacaine 0.75% + 0.5 ml CSF (Group I)
Number of subjects: 43
Study 2089295 — intervention group
Group type: EXPERIMENTAL
Intervention: Peridural analgo-anesthesia during labour and birth (continuous lumbar epidural block)
Number of subjects: 50
Study 2089295 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 50
Study 108663 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% dextrose in 0.225% NaCl
Number of subjects: 6
Study 108663 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% dextrose-amino acid solution
Number of subjects: 6
Study 108663 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% dextrose-amino acid with intravenous fat emulsion
Number of subjects: 6
Study 31494019 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback intervention group
Number of subjects: 93
Study 31494019 — intervention group
Group type: COMPARATOR
Intervention: No feedback (control group)
Number of subjects: 93
Study 28215627 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight management intervention with family member as study partner
Number of subjects: 147
Study 28215627 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight management intervention with paid assistant as study partner
Number of subjects: 147
Study 28215627 — intervention group
Group type: COMPARATOR
Intervention: Paid assistants as study partner
Number of subjects: 147
Study 26192350 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG needle and syringe (NS)
Number of subjects: 0
Study 26192350 — intervention group
Group type: EXPERIMENTAL
Intervention: PharmaJet Tropis®
Number of subjects: 0
Study 26192350 — intervention group
Group type: COMPARATOR
Intervention: Biojector 2000® (B2000)
Number of subjects: 0
Study 26192350 — intervention group
Group type: COMPARATOR
Intervention: Bioject ID Pen® (ID Pen)
Number of subjects: 0
Study 23612881 — intervention group
Group type: EXPERIMENTAL
Intervention: ANEclear anesthesia recovery device
Number of subjects: 30
Study 21623968 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) - 200 μg beclomethasone extra-fine daily for 8 weeks
Number of subjects: 93
Study 19218828 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-family therapy (n = 25)
Number of subjects: 83
Study 19218828 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-family group therapy (n = 35)
Number of subjects: 83
Study 19218828 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (n = 23)
Number of subjects: 83
Study 17462395 — intervention group
Group type: EXPERIMENTAL
Intervention: mini-CPB system
Number of subjects: 49
Study 17462395 — intervention group
Group type: COMPARATOR
Intervention: standard CPB
Number of subjects: 49
Study 14762447 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural drying
Number of subjects: 109
Study 14762447 — intervention group
Group type: COMPARATOR
Intervention: Alcohol (70% isopropyl)
Number of subjects: 109
Study 14762447 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 109
Study 11672450 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg daily)
Number of subjects: 69
Study 11672450 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (5-20 mg daily)
Number of subjects: 69
Study 9338727 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacille Calmette-Guérin (BCG) 150 mg
Number of subjects: 122
Study 9338727 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha (IFN) 54 MU
Number of subjects: 122
Study 7909875 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative risk reduction
Number of subjects: 148
Study 7909875 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute risk reduction
Number of subjects: 148
Study 7909875 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentages of event-free patients
Number of subjects: 148
Study 7909875 — intervention group
Group type: EXPERIMENTAL
Intervention: Number needed to treat
Number of subjects: 148
Study 7909875 — intervention group
Group type: EXPERIMENTAL
Intervention: Events reduction and mortality increase
Number of subjects: 148
Study 3322922 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg o.m.
Number of subjects: 285
Study 3322922 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 400 mg b.i.d.
Number of subjects: 285
Study 28746246 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant-Torque (CT) static stretching
Number of subjects: 30
Study 28746246 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant-Angle (CA) static stretching
Number of subjects: 30
Study 27327970 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) alone (AER)
Number of subjects: 13
Study 27327970 — intervention group
Group type: COMPARATOR
Intervention: HIIT combined with strength training (COM)
Number of subjects: 13
Study 27327970 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HIIT (AER) and HIIT combined with strength training (COM)
Number of subjects: 13
Study 26365989 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with extra-virgin olive oil
Number of subjects: 4152
Study 26365989 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with mixed nuts
Number of subjects: 4152
Study 26365989 — intervention group
Group type: COMPARATOR
Intervention: Control diet (advice to reduce dietary fat)
Number of subjects: 4152
Study 26365989 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-virgin olive oil (per additional 5% of calories)
Number of subjects: 4152
Study 23507375 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (300 mg orally, administered 4 hours before a match)
Number of subjects: 12
Study 23507375 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cellulose, administered 4 hours before a match)
Number of subjects: 12
Study 21199686 — intervention group
Group type: COMPARATOR
Intervention: PV isolation
Number of subjects: 67
Study 21199686 — intervention group
Group type: EXPERIMENTAL
Intervention: GP+PV ablation
Number of subjects: 67
Study 20008243 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy with lenalidomide, bortezomib, and dexamethasone
Number of subjects: 1
Study 20008243 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with a single autologous stem cell transplant
Number of subjects: 1
Study 20008243 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy
Number of subjects: 1
Study 16824730 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise prior to influenza vaccination
Number of subjects: 60
Study 16824730 — intervention group
Group type: COMPARATOR
Intervention: Resting quietly (control group)
Number of subjects: 60
Study 15108985 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal hyperbaric bupivacaine (6, 7, 8, 9, 10, 11, or 12 mg) with 10 microg intrathecal fentanyl and 200 microg intrathecal morphine
Number of subjects: 42
Study 11268890 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term oxygen therapy (LTO)
Number of subjects: 31
Study 11268890 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological management
Number of subjects: 31
Study 11268890 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical therapy (bilateral reduction of lung volume)
Number of subjects: 31
Study 11268890 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 31
Study 11268890 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional therapy (special diets)
Number of subjects: 31
Study 11268890 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-social interventions (e.g. psychotherapy, training and education)
Number of subjects: 31
Study 11268890 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation programs (variety of interventions)
Number of subjects: 31
Study 11268890 — intervention group
Group type: COMPARATOR
Intervention: Inpatient rehabilitation
Number of subjects: 31
Study 11268890 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient rehabilitation
Number of subjects: 31
Study 9847435 — intervention group
Group type: EXPERIMENTAL
Intervention: Levalbuterol 0.63 mg
Number of subjects: 362
Study 9847435 — intervention group
Group type: EXPERIMENTAL
Intervention: Levalbuterol 1.25 mg
Number of subjects: 362
Study 9847435 — intervention group
Group type: COMPARATOR
Intervention: Racemic albuterol 2.5 mg
Number of subjects: 362
Study 9847435 — intervention group
Group type: COMPARATOR
Intervention: Racemic albuterol 1.25 mg
Number of subjects: 362
Study 9847435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 362
Study 7974381 — intervention group
Group type: EXPERIMENTAL
Intervention: Trisodium citrate 129 mM
Number of subjects: 5
Study 7974381 — intervention group
Group type: COMPARATOR
Intervention: Trisodium citrate 109 mM
Number of subjects: 5
Study 2566735 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal occult blood screening test
Number of subjects: 107349
Study 2566735 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescreening every 2 years
Number of subjects: 107349
Study 2566735 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 107349
Study 31712994 — intervention group
Group type: EXPERIMENTAL
Intervention: Hinge craniotomy (HC)
Number of subjects: 283
Study 30106321 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentially inappropriate medications (PIMs)
Number of subjects: 218
Study 30106321 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering agents
Number of subjects: 218
Study 30106321 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet agents
Number of subjects: 218
Study 30106321 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholinesterase inhibitors
Number of subjects: 218
Study 30106321 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of stay in nursing home ≤10 months
Number of subjects: 218
Study 30106321 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of stay in nursing home 11-21 months
Number of subjects: 218
Study 28441522 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 62
Study 28441522 — intervention group
Group type: COMPARATOR
Intervention: Alcohol-free placebo drink
Number of subjects: 62